7 Structure-Behavioral Activity Relationships of Peptides Derived from ACTH Some Stereochemical Considerations
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
J. W. V A N N I S P E N and H . M . G R E V E N Organon Scientific Development Group, 5340 B H Oss, The Netherlands
The influence of chain length and side-chain modifica tions of ACTH-derived peptides on active avoidance behaviour in rats will be discussed. H - M e t ( O ) - G l u - H i s - P h e - D - L y s - P h e - O H (Org 2766) emerged from these studies as an orally active peptide with an increased potency and selectivity of action. Physico-chemical data (from the literature) on the reference peptide A C T H -(4-10) did not point to a preferred conformation in solution, whereas in the crystalline state an antiparallel β-pleated sheet structure was found. At the receptor site we suggested an α-helical conformation in which the Phe and Met residues are close together. Additional support for this suggestion came from the behavioural activity of [des-Tyr , Met ]enkephalin and of cyclo- ( - P h e - M e t - є A h x - ) , єAhx merely serving as a spacer. 2
1
5
T h e r e l a t i o n s h i p b e t w e e n t h e s t r u c t u r e of a s e r i e s of p e p t i d e s d e r i v e d f r o m the a d r e n o c o r t i c o t r o p i c h o r m o n e A C T H , behavioural activity
a n d the
in an a c t i v e a v o i d a n c e behaviour t e s t ,
s t u d i e d over the past 10-20
has been
y e a r s . The results obtained were quite
different f r o m those in w h i c h e n d o c r i n e a c t i v i t y r e l a t i o n s h i p s were s t u d i e d . F r o m t h e o u t c o m e of a q u a n t i t a t i v e
study on the
structure-
- b e h a v i o u r a l a c t i v i t y of t h e A C T H - r e l a t e d p e p t i d e s , s u g g e s t i o n s about the s p a t i a l
i n t e r a c t i o n s at the r e c e p t o r s i t e w e r e m a d e .
This
r e c e p t o r - b o u n d c o n f o r m a t i o n differed f r o m t h o s e s u g g e s t e d by s o l u t i o n e x p e r i m e n t s or f o u n d i n c r y s t a l
structures.
In t h i s p a p e r w e w i l l i l l u s t r a t e t h e l i n e of r e s e a r c h t h a t w a s f o l l o w e d in the s t r u c t u r e - b e h a v i o u r a l
a c t i v i t y work a n d that r e s u l t e d
0097-6156/ 84/ 0251 -0153506.00/ 0 © 1984 American Chemical Society
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
154
CONFORMATIONALLY DIRECTED DRUG DESIGN
i n a m o d i f i e d h e x a p e p t i d e w i t h a n i n c r e a s e d s e l e c t i v i t y of a c t i o n ; d i s s o c i a t i o n of a c t i v e a v o i d a n c e b e h a v i o u r a l a c t i v i t y f r o m o t h e r a c t i v i t i e s w i l l be m e n t i o n e d b r i e f l y . W e w i l l a l s o d e s c r i b e the a r g u m e n t s t h a t h a v e l e d t o t h e p r o p o s a l of a n a - h e l i c a l for t h i s h e x a p e p t i d e at t h e r e c e p t o r
conformation
site.
S t r a t e g y a n d r e s u l t s of t h e s t r u c t u r e - b e h a v i o u r a l a c t i v i t y
ACTH,
studies
a s t r a i g h t - c h a i n p e p t i d e of 3 9 a m i n o a c i d r e s i d u e s ( F i g u r e
1),
h a s b e e n t h e s u b j e c t o f e x t e n s i v e s t u d i e s b y m a n y g r o u p s . In a d d i -
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
t i o n t o s t i m u l a t i o n of t h e a d r e n a l c o r t e x i n v e r t e b r a t e a n i m a l s a n d man,
lipolytic and melanotropic effects are important,
extra-adrenal
activities
(1,
2).
a l s o affected behaviour in intact (4).
systemic,
In t h e f i f t i e s it w a s f o u n d t h a t (3)
ACTH
and hypophysectomized a n i m a l s
T h e m e l a n o c y t e - s t i m u l a t i n g h o r m o n e s a - M S H ( c o m p r i s i n g the
N-terminal
13 a m i n o a c i d r e s i d u e s of A C T H b u t w i t h b l o c k e d e n d
g r o u p s , s e e F i g u r e 1) a n d ( 3 - M S H ( c o n t a i n i n g , sequence 4-10 impairment lobe ( 5 ) .
in g e n e r a l ,
the
of A C T H ) w e r e a l s o a b l e t o c o r r e c t b e h a v i o u r a l
i n r a t s a f t e r r e m o v a l o f t h e p i t u i t a r y or o n l y i t s a n t e r i o r
S i n c e that t i m e the i n f l u e n c e of s t r u c t u r a l
modifications
of t h e s e p e p t i d e s o n b e h a v i o u r i n r a t s h a s b e e n i n v e s t i g a t e d , e s p e c i a l l y by d e W i e d a n d c o - w o r k e r s . T h e f i r s t s t e p in t h e s e s t u d i e s h a s b e e n the s e a r c h for t h e s h o r t e s t f r a g m e n t of t h e A C T H c h a i n t h a t i s e s s e n t i a l for of)
activity.
Next,
(maintenance
c h a n g e s in the peptide b a c k b o n e and m o d i f i c a -
t i o n of t h e s i d e - c h a i n s o f t h e a m i n o a c i d r e s i d u e s h a v e b e e n s t u d i e d . A s a t e s t s y s t e m t h e d e l a y of e x t i n c t i o n of a n a c t i v e a v o i d a n c e r e s p o n s e in rats a s m e a s u r e d in a p o l e - j u m p i n g test after
sub-
c u t a n e o u s a d m i n i s t r a t i o n h a s b e e n u s e d (7) ; t h i s a s s a y m e t h o d g i v e s a g r a d e d d o s e - r e s p o n s e r e l a t i o n s h i p w h i c h a l l o w s the e s t i m a t i o n of a n -(4-10)
ED50
1
and thus potency ratio s . The heptapeptide
h a s been u s e d a s the reference peptide ( 8 ) .
extensive review see ref.
I n f l u e n c e of c h a i n l e n g t h .
ACTH-
For a m o r e
9.
T h e f r a g m e n t s 1-24
a n d 1-10
were as
a c t i v e a s the w h o l e m o l e c u l e (weight b a s i s ) in d e l a y i n g e x t i n c t i o n of t h e a c t i v e a v o i d a n c e r e s p o n s e , w h e r e a s t h e C - t e r m i n a l 25-39,
18-39
(both porcine s e q u e n c e ) and 11-24
of t h a t p o t e n c y . S t e p w i s e s h o r t e n i n g f r o m t h e N - a n d , f r o m the C - t e r m i n a l
fragments
possessed
1/10th
separately,
end resulted in fragment 4 - 7 w h i c h c o n t a i n e d
a l l t h e e s s e n t i a l e l e m e n t s for a f u l l r e s p o n s e ( 1 0 ) .
ACTH-(7-10)
e x e r t e d a c o m p l e t e r e s p o n s e o n l y at a 10 t i m e s h i g h e r d o s e ;
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
this
7.
VAN NISPEN AND GREVEN
Peptide Structure-Behavioral
Activity
155
r e s i d u a l p o t e n c y c o u l d be i n c r e a s e d to the s a m e l e v e l a s the r e f e r e n c e p e p t i d e by e x t e n s i o n to A C T H - ( 7 - 1 6 ) - N H
(11).
2
c o n c l u d e d that r e g i o n s other than the 4 - 7 a l s o c o n t a i n
It
was
information
for p o l e - j u m p i n g a c t i v i t y but t h a t t h i s i s p r e s e n t i n a l a t e n t f o r m w h i c h n e e d s c h a i n e l o n g a t i o n in order to b e c o m e f u l l y e x p r e s s e d (11).
H-Ser
-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val -Tyr-Pro
2 4
-Asn-Gly-Ala-Glu-
-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe
Figure 1.
1
Val-NH
1 3 2
]ACTH-(1-13).
sequence is A C T H - ( 4 - 1 0 ) .
-OH
(6) . a - M S H
A m i n o a c i d s e q u e n c e of h u m a n A C T H [Ac-Ser ,
3 9
is
The underlined
S t a n d a r d a b b r e v i a t i o n s are
u s e d for a m i n o a c i d s : I U P A C - I U B C o m m i s s i o n o n B i o c h e m i c a l N o m e n c l a t u r e , E u r . J . B i o c h e m . 1975, 1-14;
1972,
27,
I n f l u e n c e of D - a m i n o a c i d s . w o r k , the A r g
8
53
201-7.
A s w a s f o u n d in a n e a r l y s t a g e of t h i s
r e s i d u e c o u l d be r e p l a c e d by L y s
3
(which is simpler
in a s y n t h e t i c a l s e n s e ) w i t h o u t l o s s of a c t i v i t y . T h e r e f o r e , the
L/D
3
r e p l a c e m e n t s h a v e b e e n c a r r i e d out o n the L y s - c o n t a i n i n g h e x a peptide 4 - 9 ,
i.e.
H - M e t - G l u - H i s - P h e - L y s - T r p - O H (which is as 4
5
potent a s the s e q u e n c e 4 - 1 0 ) . T h e a n a l o g u e s w i t h D - M e t ,
D-Glu ,
D - H i s ^ or D - T r p 9 w e r e a s a c t i v e a s or m o r e a c t i v e t h a n t h e a l l - L r e f e r e n c e p e p t i d e . I n c o r p o r a t i o n of D - A r g
3
in A C T H - ( 4 - 1 0 )
resulted
in a 3 - f o l d i n c r e a s e i n p o t e n c y w h e r e a s i n c o r p o r a t i o n of D - L y s the s e q u e n c e 4 - 9 r e s u l t e d in a 10-30 R e p l a c e m e n t of P h e
7
by D - P h e
7
however,
s h o w e d a r e v e r s a l of the e f f e c t i . e . extinction (12).
3
in
times more active compound. gave a compound which
a c c e l e r a t i o n i n s t e a d o f d e l a y of
Other A C T H a n a l o g u e s c o n t a i n i n g a D - a m i n o
acid
r e s i d u e i n p o s i t i o n 7 a l s o s h o w e d a c c e l e r a t i o n of e x t i n c t i o n ( 9 ) • C o m b i n a t i o n s of t w o D - a m i n o a c i d r e s i d u e s h a d d i f f e r e n t e f f e c t s . For i n s t a n c e , c o m b i n i n g D - G l u
5
or D - H i s ^ w i t h D - L y s
somewhat more active compounds. However, ACTH-(4-9)
3
r e s u l t e d in
4
[D-Met ,
D-Lys8]-
w a s l e s s a c t i v e than the reference p e p t i d e , m e a n i n g a 3
l o s s o f t h e p o t e n t i a t i n g c o n t r i b u t i o n of D - L y s . T h e c o m b i n a t i o n o f D-Met
4
and D - P h e
7
(in the L - L y s
3
containing 4-9 peptide)
i n a l o s s o f a c c e l e r a t i o n of e x t i n c t i o n ( t y p i c a l
for D - P h e
7
resulted modifica-
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
156
CONFORMATIONALLY DIRECTED DRUG DESIGN
t i o n s ) , the new a n a l o g u e b e i n g a s a c t i v e a s A C T H - ( 4 - 1 0 ) retarding e x t i n c t i o n . 7
A l s o when c o m b i n i n g D - P h e
8
[D-Phe ,
9
D-Lys , Phe ]ACTH-(4-9)
4
Met(O)
in A C T H - ( 4 - 1 0 )
in
and D - L y s
a d e l a y of e x t i n c t i o n
o b s e r v e d w i t h a r e l a t i v e p o t e n c y of o n l y
M o d i f i c a t i o n s of s i d e - c h a i n s .
7
3
a s in
was
2.
O x i d a t i o n of t h e M e t
r e s u l t e d in a 3-10
4
r e s i d u e to
times more
potent
p e p t i d e . Further o x i d a t i o n to the c o r r e s p o n d i n g s u l f o n e i n c r e a s e d the p o t e n c y t o 10 t i m e s t h a t of t h e r e f e r e n c e p e p t i d e . F i n a l l y , 8
9
[D-Lys ,
Phe ]ACTH-(4-9)
o x i d a t i o n of M e t
4
p r o d u c t t h a t w a s 1000 t i m e s a s a c t i v e a s A C T H - ( 4 - 1 0 )
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
in
to the s u l f o n e g a v e a while
corresponding sulfoxide analogue was slightly more active times A C T H - ( 4 - 1 0 ) ] .
R e p l a c e m e n t of M e t
4
by p - A l a ,
the
[3000
A i b , or V a l
d i d n o t y i e l d p e p t i d e s w i t h p o t e n c i e s g r e a t e r t h a n t h a t of t h e M e t ( 0 ) ^ m o d i f i c a t i o n . Protection against an
aminopeptidase-type
2
of d e g r a d a t i o n b y r e p l a c e m e n t of M e t (Dam)
or of M e t ( 0 2 )
4
by D a m ( 0 2 ) ,
p o t e n c y b y a f a c t o r of 3 .
Similarly,
4
by
desaminomethionine
r e s u l t e d i n a n i n c r e a s e of protection against a carboxy-
p e p t i d a s e - t y p e of d e g r a d a t i o n b y i n t r o d u c i n g t r y p t a m i n e tryptophan, Tra)
or a m p h e t a m i n e
(replacement
b y a C H g g r o u p ) at t h e C - t e r m i n a l
Tra ]ACTH-(4-9)
4
r e m o v a l of M e t activity,
4
9
respectively, 4
2
D-Lys ,
2
this
new
ACTH-(4-10).
from unmodified A C T H - ( 4 - 9 )
from A C T H - ( 4 - 1 0 )
r e s i d u e in [ M e t ( 0 ) ,
8
[Dam(0 ) ,
, resulted in a 10-fold potentiation;
a n a l o g u e i s 1 0 , 0 0 0 t i m e s a s potent a s A l t h o u g h r e m o v a l of T r p
9
D-Lys , Phe ]ACTH-(4-9)
c o n s i d e r a b l e l o s s of a c t i v i t y
or
r e s u l t e d i n n o a n d s o m e l o s s of
l e a v i n g o u t t h e N - or C - t e r m i n a l 8
Phe
g a v e a 3 - f o l d i n c r e a s e in p o t e n c y .
A c o m b i n a t i o n of b o t h t y p e s of m o d i f i c a t i o n , 9
(descarboxy-
of t h e C O O H of
amino acid
r e s u l t e d in a
( b y a f a c t o r of 1000 a n d 3 0 - 1 0 0 ,
r e s p e c t i v e l y ) . S o for p o t e n t i a t i o n t h e p r e s e n c e of t h e s i d e - c h a i n s of 4
Met(0 ) , 2
D-Lys
8
and P h e
9
s e e m s t o b e of p r i m e
importance.
A s m e n t i o n e d a b o v e , e l o n g a t i o n of t h e s e q u e n c e 7 - 1 0 -(7-16)-NH 4-10.
2
to
i n c r e a s e d t h e p o t e n c y t o t h a t of t h e r e f e r e n c e 8
R e p l a c e m e n t of A r g - T r p
9
8
9
by D - L y s - P h e
ACTHpeptide
resulted in a
100-
- f o l d i n c r e a s e i n p o t e n c y . C - or N - t e r m i n a l s h o r t e n i n g of t h i s
7-16
a n a l o g u e by o n l y one a m i n o a c i d r e s i d u e r e s u l t e d , a g a i n ,
large
d e c r e a s e of a c t i v i t y , 8
p o t e n c y of [ D - L y s , further
a s d i d o m i s s i o n of t h e G l y 9
Phe ]ACTH-(7-16)-NH
100-fold when L y s
1
1
2
1
0
in a
residue (11).
w a s r e p l a c e d by D - L y s
1
1
. A n additional
1 0 - f o l d i n c r e a s e in p o t e n c y w a s o b s e r v e d after N - t e r m i n a l of t h e l a t t e r a n a l o g u e w i t h M e t ( 0 2 ) - G l u - H i s ;
The
was increased a
elongation
the new peptide
100,000 times as active as reference A C T H - ( 4 - 1 0 )
on a
was
weight
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
Peptide Structure-Behavioral
7. VAN NISPEN AND GREVEN
Activity
157
b a s i s . T h e m o s t potent a n a l o g u e reported to date i s H - M e t ( 0 2 ) - A l a -Ala-Ala-D-Lys-Phe-Gly-D-Lys-Pro-Val-Gly-Lys-Lys-NH is 3 m i l l i o n t i m e s a s active a s A C T H - ( 4 - 1 0 ) , million times on a molar
Discussion.
which
2
i . e . m o r e than 4
base.
T h e tetrapeptide
H-Met-Glu-His-Phe-OH
est sequence which w a s a s active a s A C T H - ( 1 - 3 9 ) b a s i s . Additional information
i s the short-
on a weight
for e x t i n c t i o n o f p o l e - j u m p i n g
a v o i d a n c e behaviour s e e m s to b e s t o r e d , in a latent f o r m ,
in the
A C T H m o l e c u l e in fragments 7 - 1 0 , 1 1 - 1 3 a n d 2 5 - 3 9 ( 1 1 ) . A
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
s i m i l a r f i n d i n g w a s reported by E b e r l e a n d S c h w y z e r for m e l a n o c y t e - s t i m u l a t i n g a c t i v i t y of a - M S H f r a g m e n t s ;
they found two d i s c r e t e
m e s s a g e s e q u e n c e s for m e l a n i n d i s p e r s i o n , i . e . t h e f r a g m e n t s and 1 1 - 1 3 - N H
2
4-10
(13) .
T h e e f f e c t s of L / D s u b s t i t u t i o n s in A C T H - ( 4 - 1 0 ) p o l e - j u m p i n g behaviour were quite different activities. While A r g
8
or ( 4 - 9 ) o n
from those on hormonal
m a y be replaced by L y s
8
without l o s s of
behavioural p o t e n c y , a d r a s t i c d e c r e a s e in s t e r o i d o g e n i c a n d lipolytic effects w a s observed when the s a m e modification w a s introduced in A C T H - ( 1 - 2 4 )
(_14). D - A r g
8
and also D - H i s
6
substitu-
t i o n s s h o w e d a n i n c r e a s e i n b e h a v i o u r a l p o t e n c y but r e s u l t e d i n i n a c t i v e c o m p o u n d s w h e n t e s t e d for m e l a n o c y t e - s t i m u l a t i n g 7
(in the 6 - 1 0 fragment)
(15).
[D-Phe ]ACTH-(6-10)
reported to b e 30 t i m e s
(15) a n d 5 - 1 0 t i m e s
the a l l - L - p e p t i d e in the latter t e s t . -NH
2
activity
has been
(16) m o r e a c t i v e 4
Ac-[Nle ,
than
7
D-Phe ]ACTH-(4-10)-
w a s 10 t i m e s a s a c t i v e a s t h e L - a n a l o g u e w h e n m e a s u r e d i n
t h e f r o g s k i n a s s a y b u t a b o u t 160 t i m e s m o r e p o t e n t i n t h e l i z a r d s k i n a s s a y ( 1 7 ) . A n increase in potency w a s a l s o observed in the m o u s e m e l a n o m a a d e n y l a t e c y c l a s e a s s a y ( 1 7 ) . In t h e p o l e -jumping test,
only the L - / D - P h e
7
replacement resulted in a
r e v e r s a l of a c t i o n i . e . a c c e l e r a t i o n i n s t e a d of d e l a y of e x t i n c t i o n . 5
8
[D-Glu ,
Lys ] ACTH-(4-9)
w a s slightly more a c t i v e than the a l l -
- L - p e p t i d e in the p o l e - j u m p i n g t e s t . 5
activity,
[D-Glu ]ACTH-(4-10)
its L - G l u
5
W h e n t e s t e d for l i p o l y t i c
p o s s e s s e d o n l y 2% o f t h e a c t i v i t y of
analogue (18) . T h e s e results c l e a r l y indicated a d i s -
s o c i a t i o n b e t w e e n r e q u i r e m e n t s for b e h a v i o u r a l a c t i v i t y o n t h e o n e hand and m e l a n o c y t e - s t i m u l a t i n g Further e v i d e n c e for t h i s s t a t e m e n t substitutions
or l i p o l y t i c a c t i v i t i e s o n t h e o t h e r . c a m e f r o m d a t a of other
: o x i d a t i o n of t h e M e t r e s i d u e i n A C T H or
a-MSH
r e s u l t e d i n a m a r k e d d e c r e a s e of c o r t i c o t r o p i c ( 1 9 ) a n d m e l a n o c y t e -stimulating
( 2 0 ) a c t i v i t y but to m o r e a c t i v e c o m p o u n d s i n t h e 9
b e h a v i o u r a l a s s a y . T r p , a l s o important for the c o r t i c o t r o p i c
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
158
CONFORMATIONALLY DIRECTED DRUG DESIGN (2M, 2 2 ) ,
a c t i v i t y of A C T H
c a n n o t be r e p l a c e d by P h e without a
m a r k e d l o s s of s t e r o i d o g e n i c p o t e n c y ; t h i s i s i n c o n t r a s t t o a potentiation in the p o l e - j u m p i n g
T h e i n t r o d u c t i o n of a D - L y s i n p o s i t i o n 8 in A C T H - ( 4 - 9 ) in a 10-30
3-fold
test.
fold increase in p o l e - j u m p i n g a c t i v i t y ,
i n c r e a s e of t h e L / D s u b s t i t u t i o n s ; i n t e r e s t i n g l y ,
resulted
b y far the D-Arg
8
largest
gave only a
3 - f o l d p o t e n t i a t i o n . S i n c e the s a m e m e t a b o l i c s t a b i l i z a t i o n m a y
be
e x p e c t e d for t h o s e t w o c o m p o u n d s , t h e h i g h e r p o t e n c y for t h e D - L y s a n a l o g u e m i g h t be attributed to an i n c r e a s e in receptor a f f i n i t y .
It
w a s s u g g e s t e d b y G r e v e n a n d d e W i e d t h a t t h e f l e x i b l e s i d e - c h a i n of
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
the D - L y s r e s i d u e c a n f u n c t i o n m o r e e f f i c i e n t l y a s an e l e c t r o s t a t i c a n c h o r at the r e c e p t o r s i t e t h a n the m o r e b u l k y a n d r i g i d D - A r g s i d e - c h a i n (23)
8
.
B i o l o g i c a l a n d p h y s i c o - c h e m i c a l p r o p e r t i e s of A C T H - ( 4 - 1 0 )
and
Org 2766
B i o l o g i c a l a c t i v i t i e s in a n i m a l s .
In o r d e r t o s e e h o w t h e
i n c r e a s e i n p o t e n c y of t h e m o d i f i e d h e x a p e p t i d e -His-Phe-D-Lys-Phe-OH,
1000-fold
H-Met(C )-Glu2
c o d e d O r g 2 7 6 6 , to d e l a y e x t i n c t i o n of
p o l e - j u m p i n g behaviour w a s r e l a t e d to its e n d o c r i n e a c t i v i t i e s ,
the
effects on corticotropic, lipotropic and m e l a n o c y t e - s t i m u l a t i n g a c t i v i t y w e r e c o m p a r e d w i t h t h o s e of A C T H - ( 4 - 1 0 ) .
O n l y 1% or l e s s
of t h e s e m e n t i o n e d a c t i v i t i e s w a s p r e s e n t ( T a b l e I ) .
Studies
comparing A C T H - ( 4 - 1 0 )
a n d O r g 2766 in other
(behavioural)
situations c l e a r l y s h o w e d different structure-activity (Table I).
test
relationships
In m o s t c a s e s a c l e a r d i f f e r e n c e i n p o t e n c y ( O r g 2 7 6 6
being m o r e potent) and in s o m e c a s e s e v e n a r e v e r s e d a c t i o n w a s found (social interaction);
w h e n t e s t e d for g r o o m i n g b e h a v i o u r ,
peptides showed no effect.
R e c e n t s t u d i e s of F e k e t e a n d d e W i e d
s h o w e d t h a t O r g 2 7 6 6 h a d a l o n g e r t i m e c o u r s e of a c t i o n i n t h e and p a s s i v e a v o i d a n c e tests than A C T H - ( 4 - 1 0 ) administration (24).
both
active
after s u b c u t a n e o u s
In t h e s e l a t t e r t w o t e s t s , O r g 2 7 6 6 w a s a l s o
found to be a c t i v e after oral a d m i n i s t r a t i o n 1 0 / 4 g / k g s h o w e d oral a c t i v i t y
( a d o s e of a p p r o x .
in the a c t i v e a v o i d a n c e t e s t ;
- ( 4 - 1 0 ) w a s not a c t i v e w h e n g i v e n o r a l l y ) .
ACTH-
When dose-response
r e l a t i o n s h i p s were s t u d i e d after i n t r a c e r e b r o v e n t r i c u l a r ,
subcuta-
n e o u s a n d o r a l a d m i n i s t r a t i o n of t h e s e t w o p e p t i d e s a n d t h e s u p e r active H - M e t ( 0 ) - A l a - A l a - P h e - D - L y s - P h e - G l y - D - L y s - P r o - V a l 2
-Gly-Lys-Lys-NH
2
[1,000,000 times as active as A C T H - ( 4 - 1 0 ) 1
a weight b a s i s ] , the relative potency r a t i o s r e m a i n e d fairly
s t a n t i r r e s p e c t i v e of t h e r o u t e of a p p l i c a t i o n ( 2 3 ) . T h i s i n d i c a t e s
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
on
con-
7.
Peptide Structure-Behavioral
VAN NISPEN AND GREVEN
T a b l e I.
159
C o m p a r i s o n of a c t i v i t i e s of O r g 2 7 6 6 a n d t h e r e f e r e n c e peptide A C T H - ( 4 - 1 0 )
Activity
9
in r a t s .
Ref.
Org 2766
ACTH-(4-10)
25
1
0.01
1
0.01
i
Melanocyte-stimulating (lizard)
1
0.001
i
Pole-jumping
1
1000°
10
Passive avoidance
1
1000°
24
1
1000
d
26
1
100
27
no
28
Corticotropic (cell
s u s p e n s i o ni)
Lipolytic (in vitro,
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
Activity
rabbits)
c
(pre-retention ) A t t e n u a t i o n of C 0 2 ~ i n d u c e d amnesia Acquisition (hypox.
shuttle-box rats)
A f f i n i t y for o p i a t e r e c e p t o r Groom ing Social
yes,
weak
decrease;
interaction^
increase;
1
S t r e s s - i n d u c e d motor
stimulation
membrane
p h o s p h o r y I at i o n
33
stimulation
34
n
1
35
i n a c t i v e in
36
1
regeneration
i b i d , in a d r e n a l e c t o m i z e d
active 4-10
ng
these doses
rats
b.
active
inactive
0
a.
32
in activity
activity
Axonal nerve
31
prevents decline
inactive
Analeptic *
Synaptic
30
1000
1000
1
Self-stimulation*
29
inactive
inactive
e
Subcutaneous administration unless stated otherwise. E f f e c t w a s of longer d u r a t i o n . A l s o a c t i v e after oral
administra-
tion. c.
Post-trial
d.
A l s o a c t i v e after oral
: ACTH-(4-10)
no effect,
Org 2766
effective.
administration.
e.
Intraventricular
f.
A d m i n i s t r a t i o n in s e p t u m .
g.
R e v e r s i n g pentobarbital-induced s e d a t i o n ; intraperitoneal intracisternal
administration.
and
administration.
h.
S t i m u l a t i o n of d i p h o s p h o i n o s i t i d e ( D P I )
i.
Unpubl i shed data.
formation,
in v i t r o .
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
160
CONFORMATIONALLY DIRECTED DRUG DESIGN
that the c o m b i n a t i o n of m e t a b o l i c s t a b i l i t y
a n d transport
characteris-
t i c s i s about t h e s a m e for t h e three p e p t i d e s , a n d s u g g e s t s that t h e i n c r e a s e i n p o t e n c y for t h e t w o a n a l o g u e s of A C T H - ( 4 - 1 0 ) d u e to a n i n c r e a s e d a f f i n i t y for the r e l e v a n t
S t u d i e s in m a n . T h e a n i m a l
receptor
is mainly
site.
studies with A C T H - ( 4 - 1 0 )
and Org
2 7 6 6 h a v e s u g g e s t e d t h a t t h e s e p e p t i d e s e n h a n c e a t t e n t i o n or m o t i v a t i o n a n d that they a l s o m a y i m p r o v e m e m o r y
consolidation
( for a r e v i e w s e e 3 7 ) . S t u d i e s u s i n g a c u t e s y s t e m i c
administration
of A C T H - ( 4 - 1 0 )
intravenously)
(subcutaneously,
intramuscularly
or
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
i n d i c a t e d i n c r e a s e d s e l e c t i v e a t t e n t i o n a n d or m o t i v a t i o n volunteers and in patients -(4-10)
(38, 3 9 ) . Inconsistent
both in
e f f e c t s of A C T H -
o n t e s t s of m e m o r y a n d o t h e r t e s t s of c o g n i t i v e
performance
h a v e b e e n f o u n d ( 3 8 ) . S u b c u t a n e o u s or o r a l a d m i n i s t r a t i o n 2766 (acute studies) 39).
of O r g
have l e d to e s s e n t i a l l y the s a m e r e s u l t s
T h e s e p e p t i d e s differ f r o m
(38,
(other) p s y c h o s t i m u l a n t drugs in
that they d o not s h o w a n y u n w a n t e d
side-effects.
R e c e n t f i n d i n g s after s u b c h r o n i c , oral a d m i n i s t r a t i o n
of O r g 2 7 6 6
in d a i l y d o s e s of 1 0 - 4 0 m g , s h o w e d a d e c r e a s e i n a n x i e t y a n d depression (self-rated) and an improvement tence,
sociability and ward behaviour
of f e e l i n g s o f c o m p e -
(observer-rated)
(39) . N o
side-effects like influence on autonomic activity and appetite, no sedative effects were reported.
and
It s e e m s t h a t O r g 2 7 6 6 m a y b e a
drug to b e u s e d i n t r e a t i n g d i s t u r b a n c e s of m o o d i n the e l d e r l y a s w e l l a s s y m p t o m s of d e m e n t i a .
Many studies in these areas are
underway.
P h y s i c o - c h e m i c a l properties.
In t h e f i f t i e s a n d s i x t i e s ,
several
s t u d i e s o n t h e c o n f o r m a t i o n of A C T H i n s o l u t i o n w e r e c a r r i e d o u t . A m o n g the u s e d techniques were O R D , C D , f l u o r e s c e n c e d e p o l a r i z a t i o n s t u d i e s a n d k i n e t i c s of d e u t e r i u m h y d r o g e n e x c h a n g e (for a review s e e r e f . 2 ) . T h e results pointed to a highly flexible coil in s o l u t i o n ; however, between T y r
2
and T r p
9
[ i n A C T H - ( 1 - 2 4 ) ] a s m e a s u r e d by e x c i t a t i o n
s p e c t r o s c o p y , w a s i n better a g r e e m e n t helical structure. helical content,
w i t h s o m e f o r m o f l o o p or
In a d d i t i o n , S q u i r e a n d B e w l e y n o t e d located in the N - t e r m i n a l
and acidic pH values,
P r e d i c t i o n of t h e s e c o n d a r y s t r u c t u r e
11-15%
1-11 p a r t o f t h e m o l e c u l e ,
w h e n m e a s u r i n g t h e O R D o f A C T H at p H 8 . 1 w a s f o u n d at n e u t r a l
random
E i s i n g e r (40) f o u n d that the d i s t a n c e
(41)
(a random coil
2).
of A C T H u s i n g t h e r u l e s of
C h o u a n d F a s m a n (42) by L o w et a l . ( 4 3 ) ,
J i b s o n a n d Li (44) and
M u t t e r et a l . ( 4 5 ) , r e v e a l e d a p r e f e r e n c e for a n a - h e l i c a l
structure
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
7.
Peptide Structure-Behavioral
VAN NISPEN AND GREVEN
Activity
f o r t h e f r a g m e n t s 3 - 9 ( 4 3 ) or 2 - 9 ( 4 4 , 4 5 ) a n d 2 7 - 3 5
161
( 4 3 , 4 4 ) or
2 9 - 3 4 ( 4 5 ) a n d i n d i c a t i o n s f o r a (3-turn at 2 3 - 2 6 ( 4 3 , 4 4 , 4 5 ) a n d f
12-15
( 4 4 ) or 1 4 - 1 7 ( 4 5 ) . A p p l y i n g T a n a k a a n d S c h e r a g a s m e t h o d
( 4 6 ) , M u t t e r et a l . c a l c u l a t e d t h e a - h e l i c a l r e g i o n to b e f r a g m e n t 2-9
(45). In t h e m i d - s e v e n t i e s , L o w e t a l . s t u d y i n g A C T H - ( 1 - 3 9 )
fragments,
found a transition from random coil to a helix
and
structure
when the s o l v e n t water w a s gradually r e p l a c e d by trifluoroethanol (TFE)
( 4 3 ) . T h i s latter s o l v e n t h a d b e e n s h o w n t o favour the
e s t a b l i s h m e n t of o r d e r e d s t r u c t u r e s ( ( 3 - s h e e t or a - h e l i x )
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
membrane-receptor properties)
environment
("membrane-receptor
like a mimetic"
( 4 7 ) . S u b s e q u e n t w o r k of t h e g r o u p s of L o w a n d
Fermandjian on A C T H - ( 1 - 3 9 ) a n a l o g u e s m a k i n g u s e of
1
a n d several large fragments a n d
H - and 13C - N M R
s p e c t r o s c o p y , IR
h y d r o g e n - d e u t e r i u m e x c h a n g e k i n e t i c s a n d C D a l l p o i n t e d to h e l i c a l s t r u c t u r e s of s e q u e n c e s i n A C T H
(48, 49 and references
S m a l l A C T H f r a g m e n t s related to A C T H - ( 4 - 1 0 )
therein).
have also been
i n v e s t i g a t e d for the p r e s e n c e of o r d e r e d s t r u c t u r e . C D of A C T H -(5-10) 1
in T F E showed a random structure
H-NMR
for f r a g m e n t
(50) a s w a s found with
4 - 1 0 ( 5 1 ) . T h e a d d i t i o n o f a n i o n i c or c a t i o n i c
s u r f a c t a n t s to a n a q u e o u s s o l u t i o n of A C T H - ( 4 - 1 1 ) a n y a - h e l i x or (3-fornn i n t h i s p e p t i d e ACTH-(1-14)
d i t not p r o m o t e
( C D experiments;
52).
When
a n d 1-10 were m e a s u r e d by C D a n d N M R r e s p e c t i v e l y ,
i n d i c a t i o n s f o r a h e l i c a l or o r d e r e d s t r u c t u r e w e r e f o u n d ( 5 0 , T h u s it s e e m s t h a t t h e a d d i t i o n o f t h e n o n - h e l i x " p r o n e "
51).
fragment
1 - 3 or 1 - 4 c a n p r o m o t e t h e f o r m a t i o n o f a h e l i c a l s t r u c t u r e i n t h e a d j a c e n t s e q u e n c e . A r g u m e n t s i n favour of t h i s c o m e f r o m the t h e o r e t i c a l work of A r g o s a n d P a l a u (53) o n a m i n o a c i d d i s t r i b u t i o n in protein s e c o n d a r y s t r u c t u r e s . They found that S e r a n d Thr frequently o c c u r at t h e N - t e r m i n a l h e l i c a l p o s i t i o n ( c f . S e r ACTH)
to provide s t a b i l i t y ;
1
0
);
to T r p
9
in
a c i d i c a m i n o a c i d residues are frequently
found at the h e l i x N - t e r m i n u s r e s i d u e s at t h e C - t e r m i n u s Crystal structure(s)
in
the position adjacent to the helical
C - t e r m i n u s i s o f t e n o c c u p i e d b y G l y or P r o ( a d j a c e n t A C T H we have G l y
3
(cf. G l u
(cf.
5
in A C T H ) and/or basic
8
Arg ).
of A C T H - ( 1 - 3 9 )
or 1 - 2 4 a r e n o t k n o w n .
S u i t a b l e c r y s t a l s for X - r a y d i f f r a c t i o n e x p e r i m e n t s c o u l d b e obtained however,
for t h e h e p t a p e p t i d e 4 - 1 0 ( 5 4 , 55) a n d the
s m a l l e r tetrapeptide -parallel
4 - 7 ( 5 4 , 5 6 ) . In t h e f o r m e r c a s e ,
an anti-
( 3 - p l e a t e d s h e e t s t r u c t u r e of t h e b a c k b o n e w a s f o u n d w i t h
c l u s t e r i n g of h y d r o p h o b i c ( M e t , P h e a n d T r p ) a n d h y d r o p h i l i c ( G l u , His,
Arg) side-chains as remarkable features.
ACTH-(4-7)
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
162
CONFORMATIONALLY DIRECTED DRUG DESIGN
c r y s t a l l i z e s as a monohydrate horseshoe-1 ike structure w h i c h is a g a i n c h a r a c t e r i z e d b y t h e p r o x i m i t y of t h e h y d r o p h o b i c P h e a n d a n d t h e h y d r o p h i l i c G l u a n d H i s r e s i d u e s , but n o w v i a i n t r a i n t e r - c h a i n i n t e r a c t i o n s . S o in two quite different s t r u c t u r e s of A C T H - ( 4 - 1 0 )
conformational
and 4-7 a striking c o m m o n feature is
that the P h e a n d M e t s i d e - c h a i n s are c l o s e t o g e t h e r .
Org 2766 has
n o t y e t y i e l d e d c r y s t a l s s u i t a b l e e n o u g h for s t r u c t u r e
determination.
In s u m m a r y ,
theoretical
a p p r o a c h e s point to the p o t e n t i a l
a n a - h e l i c a l s t r u c t u r e for t h e f r a g m e n t 4 - 1 0
and the
for
conformation
f o u n d i n s o l u t i o n s of t h i s a n d s e v e r a l o t h e r f r a g m e n t s of A C T H to be c o n f i r m a t o r y ;
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
Met
and
the c r y s t a l structure r e v e a l s a n
seem
antiparallel
[3-pleated s h e e t .
S u g g e s t i o n for c o n f o r m a t i o n at t h e r e c e p t o r s i t e for
pole-jumping
activity
In 1977 a q u a n t i t a t i v e s t u d y o n t h e r e l a t i o n s h i p b e t w e e n t h e
structure
a n d p o l e - j u m p i n g b e h a v i o u r of A C T H - d e r i v e d p e p t i d e s ( o n l y
those
that d e l a y e d e x t i n c t i o n ) ,
w a s p e r f o r m e d (1_1,
57)
a c c o r d i n g to
m e t h o d of F r e e a n d W i l s o n a s m o d i f i e d b y F u j i t a a n d B a n
(58).
A p p a r e n t l y t h e d a t a o n 5 5 p e p t i d e s s a t i s f i e d t h e c o n d i t i o n s for a mathematical
such
a p p r o a c h w h i c h m e a n s t h a t t h e p o t e n c i e s of t h e
a n a l o g u e s c o u l d b e c o n s i d e r e d t o b e c o m p o s e d of t h e p r o d u c t of independent group c o n t r i b u t i o n s f r o m individual s u b s t i t u t i o n s in the p e p t i d e c h a i n . F o r i n s t a n c e , t h e c o m b i n a t i o n of D - L y s D-Glu
5
or D - H i s
However,
8
8
with either
gave the s a m e actual and c a l c u l a t e d a c t i v i t i e s .
when D - L y s
8
was c o m b i n e d with D - M e t
-Glu-His-Phe-D-Lys-Trp-OH,
4
a s in
the o b s e r v e d potency w a s
H-D-Metmuch
l o w e r t h a n t h e c a l c u l a t e d o n e . S i n c e t h i s i s o n e of t h e v e r y e x c e p t i o n s where the c a l c u l a t i o n f a i l e d ,
i.e.
independent group c o n t r i b u t i o n s w a s no longer f u l f i l l e d w a s s u g g e s t e d by G r e v e n a n d de W i e d (11) s t e r i c i n t e r f e r e n c e of t h e D - M e t
4
few
t h e c o n d i t i o n of (outlier),
it
that t h i s c o u l d be d u e to
and D - L y s
8
residues, which
in
t u r n i m p l i e s t h a t p o s i t i o n s 4 a n d 8 a r e c l o s e t o g e t h e r at t h e r e c e p t o r s i t e . T h e a m i n o a c i d s in b e t w e e n s e e m to s e r v e m e r e l y a s a s p a c e r a s w a s s h o w n b y r e p l a c e m e n t of t h e s e a m i n o a c i d s b y s i m p l e , neutral a l a n i n e r e s i d u e s ( 1 1 ) .
T h i s c l o s e p r o x i m i t y of t h e s i d e -
- c h a i n s of r e s i d u e s 4 a n d 8 i s p o s s i b l e w h e n t h e b a c k b o n e a s s u m e s an a - h e l i c a l conformation ( 1 1 ) . and P h e
7
In t h i s h e l i c a l s t r u c t u r e t h e
Met
4
r e s i d u e s are e x t r a - c h a i n n e i g h b o u r s .
T h e (3-lipotropin fragments H - T y r - G l y - G l y - P h e - M e t - O H -enkephalin)
(Met-
a n d H - G l y - G l y - P h e - M e t - O H s h o w t h e p r e s e n c e of P h e
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
7.
Peptide Structure-Behavioral
VAN NISPEN A N D G R E V E N
Activity
163
and M e t a s i n t r a - c h a i n n e i g h b o u r s . W h e n these two m o l e c u l e s were t e s t e d for d e l a y of e x t i n c t i o n i n the p o l e - j u m p i n g t e s t , f o u n d to b e a p p r o x . a s a c t i v e a s A C T H - ( 4 - 1 0 )
(23,
they were
9).
In a d d i t i o n ,
o x i d a t i o n of M e t t o M e t ( O ) r e s u l t e d i n a s i m i l a r p o t e n t i a t i o n a s t h a t f o u n d i n the A C T H s e r i e s . T h e h y p o t h e s i s that the c l o s e p r o x i m i t y of a P h e and M e t r e s i d u e in A C T H - and enkephalin-1 ike p e p t i d e s i s e s s e n t i a l for a d e l a y i n e x t i n c t i o n w a s f u r t h e r c h e c k e d b y t e s t i n g a c y c l i c peptide containing P h e , Met and a spacer e-aminohexanoic a c i d O s A h x ) t o c l o s e t h e r i n g [ s A h x w a s c h o s e n s i n c e it c o n t a i n s
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
no f u n c t i o n a l g r o u p s a n d d o e s not d i s t o r t the p e p t i d e g r o u p s s i g n i f i c a n t l y f r o m p l a n a r i t y or f o r c e t h e m i n t o t h e c i s c o n f o r m a t i o n
(59)].
Cyclo-(-Phe-Met-gAhx-)
ACTH-
-(4-10)
(60)
w a s f o u n d to be a s a c t i v e a s
in d e l a y i n g extinction ( 9 ) ,
of G r e v e n a n d d e W i e d
thus supporting the h y p o t h e s i s
(11).
A s mentioned before ( s e c t i o n 1 ) , r e s i d u e in the A C T H f r a g m e n t 4 - 1 0
i n t r o d u c t i o n of t h e D - L y s
or 4 - 9 r e s u l t e d i n a h i g h e r
i n c r e a s e in a c t i v e a v o i d a n c e behaviour than the 3 - f o l d i n c r e a s e in a c t i v i t y w h e n L - A r g w a s r e p l a c e d by D - A r g , s u g g e s t i n g an a d d i t i o n a l f u n c t i o n of t h e D - L y s r e s i d u e at t h e r e c e p t o r s i t e . T h e m e r e p r e s e n c e of D - L y s , M e t ( O )
or M e t ( 0 ) 2
and P h e in one m o l e c u l e a s in Org
2 7 6 6 i s n o t s u f f i c i e n t , h o w e v e r , for h i g h a c t i v i t y
in the
pole-jumping
test. When H - G l y - G l y - P h e - M e t ( O ) - D - L y s - P h e - O H was tested, a c c e l e r a t i o n i n s t e a d of d e l a y o f e x t i n c t i o n w a s f o u n d . T h e corresponding a l l - L hexapeptide delayed extinction and was as active as A C T H - ( 4 - 1 0 )
(Greven and de W i e d , unpublished results) . A
s p e c i a l s p a t i a l a r r a n g e m e n t of t h e s e t h r e e r e s i d u e s at t h e r e c e p t o r for p o l e - j u m p i n g a c t i v i t y t h e r e f o r e a p p e a r s t o b e a r e q u i r e m e n t high activity
for
i n d e l a y i n g e x t i n c t i o n of a c o n d i t i o n e d a v o i d a n c e
response. S u g g e s t e d preferred c o n f o r m a t i o n s c a n be f i x e d by c y c l i z a t i o n . C y s t i n e h a s b e e n u s e d to o b t a i n c y c l i c a n a l o g u e s of O r g 2 7 6 6 v i z . H-Cys-Glu-His-Cys-D-Lys-Phe-OH,
H-Cys-Ala-Ala-"Cys-D-Lys-
- P h e - O H and H - C y s - A l a - A l a - P h e - D - L y s - C y s - O H
(patent a p p l i c a -
t i o n 0 0 5 2 0 2 8 of R o u s s e l - U c l a f ) , a n d t h e p e p t i d e s w e r e t e s t e d for activity
in the p o l e - j u m p i n g t e s t .
Unfortunately,
one cannot
con-
c l u d e f r o m t h e i r d a t a if c y c l i z a t i o n h a s r e s u l t e d i n a n i n c r e a s e or d e c r e a s e in a c t i v i t y s i n c e no r e f e r e n c e p e p t i d e h a s b e e n i n c l u d e d to 5
c o m p a r e p o t e n c i e s . In t h e l i t e r a t u r e c y c l i z a t i o n o f [ L y s ] A C T H -(5-10)
(the C O O H g r o u p of G l y
1
0
with the £ - N H
5
2
f u n c t i o n of L y s )
h a s been reported; the r e s u l t i n g peptide w a s i n a c t i v e in s t e r o i d o g e n e s i s ( 6 1 ) . I n c r e a s e of t h e r i n g s i z e w i t h t h r e e a t o m s G l y r e s i d u e ) , h o w e v e r , r e s u l t e d in a p e p t i d e that w a s m o r e
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
(a
active
164
CONFORMATIONALLY DIRECTED DRUG DESIGN
than the linear u n m o d i f i e d 5 - 1 0
s e q u e n c e (61.)
indicating
s
the
i m p o r t a n c e of t h e r i n g s i z e . C y c l i z a t i o n of t h e m e s s a g e s e q u e n c e for s t e r o i d o g e n i c a c t i v i t y b y r e p l a c e m e n t of G l u c y s t i n e residue in [ 2 - $ - a m i n o v a l e r i c
5
and G l y ^ by a
acid]ACTH-(2-19)
r e s u l t e d in
a 5 0 - f o l d d e c r e a s e in steroidogenic activity and 10-fold d e c r e a s e in lipolytic activity
(62).
When a cystine molecule was
i n t o a - M S H i n p l a c e of M e t
4
and G l y
1
0
incorporated
, a very potent a n a l o g u e w a s
o b t a i n e d w i t h a p o t e n c y > 1 0 , 0 0 0 t i m e s t h a t of a - M S H i n frog s k i n d a r k e n i n g a n d about 30 t i m e s m o r e potent w h e n in vitro in lizard s k i n
stimulating measured
(63).
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
T h u s s t r o n g p o t e n t i a t i o n of b i o l o g i c a l a c t i v i t y c a n b e o b t a i n e d e i t h e r b y s u b s t i t u t i o n s w h i c h a l l o w or e n h a n c e a p r e f e r r e d c o n f o r m a t i o n at t h e r e c e p t o r s i t e or b y f i x a t i o n o f s u c h a p r e f e r r e d c o n f o r m a t i o n v i a c y c l i z a t i o n of t h e b a c k b o n e .
Concluding
remarks
F o r a c t i v i t y of A C T H - d e r i v e d p e p t i d e s at t h e r e c e p t o r for ing a c t i v i t y ,
the b a s i c requirement
P h e and M e t r e s i d u e in c l o s e p r o x i m i t y . P h e and M e t are c l o s e together
pole-jump-
s e e m s to b e the p r e s e n c e of a It i s i n t e r e s t i n g t o s e e t h a t
in an a - h e l i c a l structure in A C T H
p e p t i d e s ( a n d a s i n t r a - c h a i n n e i g h b o u r s in M e t - e n k e p h a l i n ) the c r y s t a l l i n e state in A C T H - ( 4 - 1 0 ) ACTH-(4-7)
and in
a s a [3-pleated sheet a n d in
i n t h e f o r m of a h o r s e s h o e ; t h i s c l o s e p r o x i m i t y
is in
l i n e w i t h t h e r e s u l t s of a F r e e - W i l s o n t y p e of a n a l y s i s . In H - M e t ( C ) - G l u - H i s - P h e - D - L y s - P h e - O H ( O r g 2 7 6 6 ) , 2
large i n c r e a s e in activity
in the p o l e - j u m p i n g test a n d the
the
longer
d u r a t i o n of a c t i o n c a n o n l y p a r t l y b e e x p l a i n e d b y a n i n c r e a s e i n stability.
It i s s u g g e s t e d t h a t i n t h e f o r m of a n a - h e l i x or l o o p - 1 i k e
s t r u c t u r e at t h e r e c e p t o r s i t e , Met(0 ) 2
4
and P h e
9
t h e p r e s e n c e of D - L y s
3
as well
c o n t r i b u t e s t o a n i n c r e a s e of r e c e p t o r
as
affinity.
Literature Cited 1. Hofmann, K. in "Handbook of Physiology, Section 7 : Endocrinology, vol. IV, The pituitary gland and its neuroendocrine control, Part 2; Greep, R . O . ; Astwood, E.B., E d s . ; Waverly Press : Baltimore, 1974; pp.29-58. 2. Schwyzer, R. Ann. N.Y. Acad. S c i . 1977, 297, 3-26. 3. Mirsky, I.A.; Miller, R.; Stein, M. Psychosom. Med. 1953, 15, 574-88.
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
7.
VAN
NISPEN
AND
GREVEN
Peptide Structure-Behavioral
Activity
165
4. Applezweig, M.H.; Baudry, F.D. Psychol. Rep. 1955, 1, 417-20. 5. De Wied, D. in "Frontiers in Neuroendocrinology"; Ganong, W.F.; Martini, L., Eds.; Oxford Univ. Press : London; 1969, pp. 97-140. 6. Riniker, B.; Sieber, P.; Rittel, W.; Zuber, H. Nature (New Biol.) 1972, 235, 114-5. 7. De Wied, D. Proc. Soc. Exp. Biol. Med. 1966, 122, 28-32. 8. Greven, H.M.; de Wied, D. Eur. J , Pharmacol. 1967, 2, 14-6. 9. Nispen, J.W. van; Greven, H.M. Pharmac. & Ther. 1982, 16, 67-102. 10. Greven, H.M.; de Wied, D. in "Progress in Brain Research"; Zimmermann, E.; Gispen, W.H.; Marks, B.H.; de Wied, D., Eds.; Elsevier : Amsterdam, 1973; Vol. 39, pp.429-41. 11. Greven, H.M.; de Wied, D. in "Frontiers of Hormone Research"; van Wimersma Greidanus, Tj. B., Ed.; Karger : Basel, 1977; Vol. 4, pp. 140-152. 12. Bohus, B.; de Wied, D. Science 1966, 153, 318-20. 13. Eberle, A.; Schwyzer, R. Helv. Chim. Acta 1975, 58, 1528-35. 14. Tesser, G.I.; Maier, R.; Schenkel-Hulliger, L.; Barthe, P.L.; Kamber, B.; Rittel, W. Acta Endocrinol. 1973, 74, 56-66. 15. Yajima, H.; Kubo, K.; Kinomura, Y.; Lande, S. Biochim. Biophys. Acta 1966, 127, 545-9. 16. Schnabel, E.; Li, C.H. J. Am. Chem. Soc. 1960, 82, 4576-9. 17. Sawyer, T.K.; Hruby, V . J . ; Wilkes, B.C.; Draelos, M.T.; Hadley, M.E.; Bergsneider, M. J . Med. Chem. 1982, 25, 1022-7. 18. Draper, M.W.; Rizack, M.A.; Merrifield, R.B. Biochemistry 1975, 14, 2933-8. 19. Dedman, M.L.; Farmer, T.H.; Morris, G.J.O.R. Biochem. J . 1955, 59, xii. 20. Lo, T.-B.; Dixon, J.S.; Li, C.H. Biochim. Biophys. Acta 1961, 53, 584-6. 21. Hofmann, K.; Andreatta, R.; Bohn, H.; Moroder, L. J . Med. Chem. 1970, 13, 339-45. 22. Nispen, J.W. van; Tesser, G.I. Int. J . Peptide Prot. Res. 1975, 7, 57-67.
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
166
CONFORMATIONALLY DIRECTED DRUG DESIGN
23. Greven, H.M.; de Wied, D. in "Hormones and the Brain"; de Wied, D.; van Keep, P.A., Eds.; MTP : Falcon House, 1980; pp. 115-127. 24. Fekete, M.; de Wied, D. Pharmacol. Biochem. Behav. 1982, 16, 387-92. 25. Krieger, D.T., communication to Organon. 26. Rigter, H.; Janssens-Elbertse, R.; van Riezen, H. Pharmacol. Biochem. Behav. 1976, 5 (suppl. 1), 53-8. 27. Fekete, M.; Bohus, B.; de Wied, D. Neuroendocrinol. 1983, 36, 112-8. 28. Gispen, W.H.; Terenius, L., communication to Organon. 29. Gispen, W.H.; Wiegant, V.M.; Greven, H.M.; de Wied, D. Life Sci. 1975, 17, 645-52. 30. Clarke, A.; File, S.E. Br. J. Pharmacol. 1981, 74, 277P. 31. Fekete, M.; Bohus, B.; van Wolfswinkel, L.; van Ree, J.M.; de Wied, D. Neuropharmacol. 1982, 21, 909-16. 32. Saint-CÔme, C.; Acker, G.R.; Strand, F.L. Peptides 1982, 3, 439-49. 33. Bissette, G.; Nemeroff, C.B.; Loosen, P.T.; Prange A.J., Jr.; Lipton, M.S. Pharmacol. Biochem. Behav. 1976, 5 (suppl. 1), 135-8. 34. Jolles, J.; Bär, P.R.; Gispen, W.H. Brain Res. 1981, 224, 315-26. 35. Bijlsma, W.A.; Jennekens, F.G.I.; Schotman, P.; Gispen, W.H. Eur. J. Pharmacol. 1981, 76, 73-9. 36. Smith, C.M.; Strand, F.L. Peptides 1981, 2, 197-206. 37. Bohus, B. Pharmacol. 1979, 18, 113-22. 38. Gaillard, A.W.K., in "Endogenous Peptides and Learning and Memory Processes"; Martinez, J.L.; Jensen, R.A.; Messing, R.B.; Rigter, H.; McGaugh, J.L., Eds.; Academic : New York, 1981; pp. 181-196. 39. Pigache, R.M.; Rigter, H. in "Frontiers of Hormone Research"; van Wimersma Greidanus, Tj.B.; Rees, L.H., Eds.; Karger : Basel, 1981; Vol. 8, pp. 193-207. 40. Eisinger, J . Biochemistry 1969, 8, 3902-7. 41. Squire, P.G.; Bewley, T. Biochim. Biophys. Acta 1965, 109, 234-40. 42. Chou, P.Y.; Fasman, G.D. Biochemistry 1974, 13, 222-45. 43. Löw, M.; Kisfaludy, L.; Fermandjian, S. Acta Biochim. et Biophys. Acad. Sci. Hung. 1975,10,229-31. 44. Jibson, M.D.; Li, C.H. Int. J . Peptide Prot. Res. 1979, 14, 113-22.
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.
Downloaded by NATL UNIV OF SINGAPORE on May 6, 2018 | https://pubs.acs.org Publication Date: April 24, 1984 | doi: 10.1021/bk-1984-0251.ch007
7. VAN NISPEN AND GREVEN
Peptide Structure-Behavioral Activity167
45. Mutter, H.; Mutter, M.; Bayer, E. Z. Naturforsch. 1979, 34b, 874-85. 46. Tanaka, S.; Scheraga, H.A. Macromolecules 1977, 10, 305-16, and references therein. 47. Urry, D.W.; Masotti, L.; Krivacic, J.R. Biochim. Biophys. Acta 1971, 241, 600-12. 48. Toma, F.; Dive, V.; Lam-Thanh, H.; Piriou, F.; Lintner, K.; Fermandjian, S.; Löw, M.; Kisfaludy, L. Biochimie 1981, 63, 907-10. 49. Toma, F.; Fermandjian, S.; Low, M.; Kisfaludy, L. Biopolymers 1981, 20, 901-13. 50. Greff, D.; Toma, F.; Fermandjian, S.; Löw, M.; Kisfaludy, L. Biochim. Biophys. Acta 1976, 439, 219-31. 51. Rawson, B.J.; Feeney, J . ; Kimber, B.J.; Greven, H.M. J. Chem. Soc. Perkin Trans. II 1982, 1471-7. 52. Wu, C.-S.; Yang, J.T. Biochem. Biophys. Res. Commun. 1978, 82, 85-91. 53. Argos, P.; Palau, J. Int. J. Peptide Prot. Res. 1982, 19, 380-93. 54. Admiraal, G. Ph. D. Thesis, Groningen State University, Groningen, 1981. 55. Admiraal, G.; Vos, A. Int. J. Peptide Prot. Res., in press. 56. Admiraal, G.; Vos, A. Acta CrystalIogr., Sect. C 1983, C39, 82-7. 57. Kelder, J . ; Greven, H.M. Recl. Trav. Chim. Pays-Bas 1979, 98, 168-72. 58. Fujita, T.; Ban, T. J. Med. Chem. 1971, 14, 148-52. 59. Némethy, G.; McQuie, J.R.; Pottle, M.S.; Scheraga, H.A. Macromolecules 1981, 14, 975-84. 60. Nispen, J.W. van ; Greven, H.M. Recl. Trav. Chim. Pays-Bas 1982,101,451-5. 61. Romanovskis, P.J.; Siskov, I.V.; Liepkaula, I.K.; Porunkevich, E.A.; Ratkevich, M.P.; Skujins, A.A.; Chipens, G.I. Proc. 7th American Peptide Symp. 1981, pp. 229-32. 62. Blake, J . ; Rao, A.J.; Li, C.H. Int. J. Peptide Prot. Res. 1979, 13, 346-52. 63. Sawyer, T.K.; Hruby, V.J.; Darman, P.S.; Hadley, M.E. Proc. Natl. Acad. Sci. USA 1982, 79, 1751-5. RECEIVED November
15, 1983
Vida and Gordon; Conformationally Directed Drug Design ACS Symposium Series; American Chemical Society: Washington, DC, 1984.